Trial Profile
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tazarotene (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 30 Oct 2008 Planned end date changed from 1 Jun 2010 to 1 Jun 2011, based on information from ClinicalTrials.gov.
- 30 Oct 2008 Planned end date changed from 1 Jun 2010 to 1 Jun 2011, based on information from ClinicalTrials.gov.
- 11 Mar 2008 Added trial centre, from NCT.